CORE--CLINICAL

临床核心(CC)将为招募、表征和登记以下人员提供一个结构 参与CCNMD的患者提出了研究方案，特别是Abi-Dargham和Laruelle的项目，同时保持最高的安全和道德标准。核心任务将包括： 1)招聘。招募将集中进行，并将针对广泛的患者 精神分裂症包括首发患者；慢性急性加重期患者；病情稳定的门诊患者；慢性住院患者S在国家医疗机构。控制组将从纽约州精神病研究所(NYSPI)的正常控制组招募。 2)诊断/评估。我们将严格诊断参加CCNMD的患者S 研究方案，并在精神病理学的多个领域(例如，与特征相关的症状、病程和神经认知变量)描述他们的情况。我们将通过集中培训评分员来实现和保持评分员之间的相互责任，以确保随着时间的推移评估和措施的一致性。 3)我们将监督NYSPT精神分裂症研究室(SRU)不同方案之间的患者流动，以及他们在精神分裂症研究诊所(SRC)的治疗和随访。我们还将收集用于遗传学研究的血液样本，这些样本将集中在康拉德·吉利亚姆的基因组中心。 4)Eillics和安全委员会：该委员会将审查所有研究的伦理方面。特别是，与脆弱人群中的药物冲刷和能力评估有关的问题将是该委员会关注的中心，以确保研究对象的保护和安全。

The Clinical Core (CC) will provide a structure for recruitment, characterization and enrollment of patients involved in the CCNMD proposed research protocols, in particular projects by Abi-Dargham and Laruelle, while maintaining the highest standards of safety and ethics. Missions of the core will include: 1) Recruitment. Recruitment will be centralized and will target a broad range of patients with schizophrenia including first episode patients; chronic patients in acute exacerbation; stable outpatients; chronic inpatient s in state facilities. Controls wilt be recruited from the Normal Controls Unit at the New York State Psychiatric Institute (NYSPI). 2) Diagnosis / Assessment. We will rigorously diagnose patients participating in the CCNMD' s research protocols and characterize their conditions across multiple domains of psychopathology (e.g. trait-related symptom, course of illness, and neurocognitive variables). We will ensure uniformity of assessmenfs and measures over timei by centralizing the training of raters to achieve and maintain interrater reiiability. 3) We will oversee the flow of patients between the dlfferent protocols while oni the Schizophrenia Research Unit at NYSPt (SRU), and their treatment and follow up in the Schizophrenia Research Clinic (SRC). We will also colllect blood samples for genetic studies which will be centralized in Conrad Giiiiam's Genome Center. 4) Committee for Eillics and Safety: This committee will review the ethical aspects of all studies. In particular, issues relating to medication washouts and capacity evaluations in vulnerable populations will be at the center of this committee's concerns, to ensure protection and safety of research subjects.